Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RO7017773 Phase I Capsule
RO7017773 Phase I · 1 trial · 1 indication
Taste was assessed using a questionnaire that asking participants to rate the overall taste of study drug dispersed in various vehicles on a scale from 1-5, with 1=no taste, and 5=very intense taste.
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses. |
| Part 2 | EXPERIMENTAL | Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses. |
| Name | Type | Description |
|---|---|---|
| RO7017773 Phase I Capsule | DRUG | Participants will receive 1 single oral dose of RO7017773 Phase I Capsule. |
| RO7017773 Phase II Tablet Unflavored | DRUG | Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2. |
| RO7017773 Phase II Tablet Sweetened/Flavored | DRUG | Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2. |
Inclusion Criteria * Non-smoker for at least six months * Healthy, as judged by the Investigator * Women of non-childbearing potential (WONCBP) who are not pregnant or lactating * Men must be willing to remain abstinent or agree to use contraceptive measures with partners who are women of childbear...
RO7017773 Phase I is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy volunteers, not in patients with a disclosed disease. The program is in early clinical development, and no approved indication has been announced.
RO7017773 Phase I is made by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the developer of the compound and sponsored the Phase 1 study that evaluated it in healthy participants.
RO7017773 Phase I is in Phase 1 development. One Phase 1 trial has been completed, and no later-stage trials have been registered. The drug remains investigational and has not been approved by the FDA for any indication.
RO7017773 Phase I has been studied in one completed Phase 1 trial, NCT03847987. The study assessed the relative bioavailability of a tablet formulation compared with a capsule formulation and the effect of food and taste on the tablet formulation in 24 healthy participants in the United States.
Yes, RO7017773 Phase I Capsule is another name for RO7017773 Phase I. Both refer to the same Roche small molecule program. The capsule name reflects the capsule formulation used in the Phase 1 trial, which also compared a tablet formulation.